Core Viewpoint - The company primarily focuses on domestic sales, with a small proportion of overseas sales revenue, and does not export to EU countries [1] Group 1 - The main business products of the company are primarily sold domestically [1] - The overseas sales revenue constitutes a minor part of the overall revenue [1] - The countries to which the company exports do not include any EU member states [1]

Core Viewpoint - The company primarily focuses on domestic sales, with a small proportion of overseas sales revenue, and does not export to EU countries [1] Group 1 - The main business products of the company are primarily for domestic sales [1] - The overseas sales revenue constitutes a small percentage of the total revenue [1] - The countries to which the company exports do not include any EU member states [1]

Core Insights - The biopharmaceutical sector experienced a decline of 0.98% on November 18, with He Yuan Bio leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Stock Performance Summary - Notable gainers included: - Aopu Mai (688293) with a closing price of 58.80, up 3.38% on a trading volume of 15,900 shares and a transaction value of 93.39 million [1] - Jin Hu Ke (688670) at 26.80, up 2.88% with a volume of 116,300 shares and a transaction value of 319 million [1] - Te Bao Bio (688278) at 77.08, up 1.22% with a volume of 10,800 shares and a transaction value of 82.57 million [1] - Notable decliners included: - Bu Yuan Bio (688765) at 79.95, down 3.89% with a volume of 56,800 shares and a transaction value of 458 million [2] - San Sheng Guo Jian (688336) at 67.60, down 3.87% with a volume of 68,100 shares and a transaction value of 469 million [2] - Wo Wu Bio (300357) at 31.77, down 3.23% with a volume of 77,900 shares and a transaction value of 250 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 981 million from institutional investors, while retail investors contributed a net inflow of 819 million [2] - Key stocks with significant capital flow included: - Hua Lan Vaccine (301207) with a net inflow of 48.51 million from institutional investors [3] - Rong Chang Bio (688331) with a net inflow of 23.62 million from institutional investors [3] - Jin Ke (688670) with a net inflow of 5.53 million from institutional investors [3]

Group 1 - The company, TeBao Bio, announced that it will hold the 14th meeting of the 9th Board of Directors on November 17, 2025, to review the proposal for external donations [2]

Core Viewpoint - The company is committed to supporting children with growth hormone deficiency through a charitable initiative, addressing both health and economic challenges faced by affected families [1] Group 1: Company Initiatives - The company has developed a national class 1 new drug, Yipeisheng (怡培生长激素注射液), for treating growth hormone deficiency in children aged 3 and above [1] - The company has decided to donate up to 40,000 doses of Yipeisheng and up to 661,600 RMB in cash to the Beijing Hongxin Xiangtong Charity Foundation to support the "Yilu Xiangban" patient assistance project [1] Group 2: Industry Context - Growth hormone deficiency in children can lead to various issues, including reduced height, lower quality of life, and potential behavioral, cognitive, and psychological disorders [1] - The initiative aligns with the "Healthy China 2030" planning outline, aiming to provide continuous and standardized treatment for more children in need [1]

厦门特宝生物工程股份有限公司 章程 2025 年 11 月 | 第一章 | 总则 | | 3 | | --- | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 4 | | | 第三章 | 股份 | | 4 | | 第一节 | 股份发行 | 4 | | | 第二节 | 股份增减和回购 | 5 | | | 第三节 | 股份转让 | 6 | | | 第四章 | 股东和股东大会 | 7 | | | 第一节 | 股东 | | 7 | | 第二节 | 股东大会的一般规定 | 9 | | | 第三节 | 股东大会的召集 | 14 | | | 第四节 | 股东大会的提案与通知 | | 15 | | 第五节 | 股东大会的召开 | 16 | | | 第六节 | 股东大会的表决和决议 | | 19 | | 第五章 | 董事会 | 24 | | | 第一节 | 董事 | 24 | | | 第二节 | 董事会 | 27 | | | 第六章 | 总经理及其他高级管理人员 | 32 | | | 第七章 | 监事会 | 34 | | | 第一节 | 监事 | 34 | | | 第二节 | 监事会 | 35 | | ...

证券代码：688278 证券简称：特宝生物 公告编号：2025-042 由于公司注册资本及总股本发生变更，根据《中华人民共和国公司法》《中 华人民共和国证券法》《上市公司章程指引》《上海证券交易所科创板股票上市 规则》等相关规定，结合实际情况，公司拟对《公司章程》相关条款进行修订， 具体内容如下： 1 厦门特宝生物工程股份有限公司 关于变更注册资本并修订《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 厦门特宝生物工程股份有限公司（以下简称"公司"）于 2025 年 11 月 17 日召开第九届董事会第十四次会议，审议通过《关于变更公司注册资本并修订< 公司章程>的议案》。根据公司 2024 年第一次临时股东大会就办理限制性股票激 励计划相关事项对董事会的授权，本次变更公司注册资本及修订《公司章程》 无需再提交股东大会审议。现将有关情况公告如下： 一、变更公司注册资本的相关情况 鉴于公司 2024 年限制性股票激励计划首次授予部分第一个归属期的归属条 件已经成就，本次归属新增股份数量为 1,389,480 ...

证券代码：688278 证券简称：特宝生物 公告编号：2025-041 厦门特宝生物工程股份有限公司 关于对外捐赠的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 厦门特宝生物工程股份有限公司（以下简称"公司"）于 2025 年 11 月 17 日 召开第九届董事会第十四次会议，审议通过《关于对外捐赠的议案》，具体情况 如下： 一、捐赠事项概况 根据《公司章程》等规定，本次对外捐赠无需提交公司股东大会审议，不涉 及关联交易，同时董事会授权公司管理层在上述捐赠范围内办理与本次捐赠相关 事项。 二、本次捐赠的对象 北京红心相通公益基金会是在北京市民政局登记注册的具有独立法人地位 的社会性慈善组织，基金会秉承"人道、博爱、奉献"的红十字精神，持续开展 1 因病致贫、因病返贫患者及家庭的援助工作，基金会自成立以来先后开展了一系 列公益援助项目，获得了来自社会各界的一致认可和广泛好评。 三、本次捐赠对公司的影响 本次对外捐赠是公司积极履行社会责任、回馈社会的具体举措。本次对外捐 赠的药品为公司自有产品，现金来源于自有资金，不会 ...

Investment Rating - The report continues to recommend the innovative drug and medical device industry chain, indicating a high level of investment interest in this sector [1][5]. Core Views - The report highlights the high prosperity in innovative drugs, suggesting potential value revaluation for companies such as Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [2][5]. - It emphasizes the importance of Biopharma/Biotech companies with innovative pipelines and performance entering a volume increase phase, including Innovent Biologics, BeiGene, and others [2][5]. - The report also points out the recovery potential for leading medical equipment companies like United Imaging Healthcare, Lepu Medical, and others [2][5]. Summary by Sections A-Shares Performance - In the second week of November 2025, the A-Shares pharmaceutical sector outperformed, with the SW Pharmaceutical and Biological index rising by 3.3% while the SHCOMP fell by 0.2% [2][30]. - The pharmaceutical commerce, chemical raw materials, and chemical preparations sub-sectors showed strong performance, with increases of 5.7%, 5.1%, and 4.4% respectively [2][30]. - Notable stock gains included GDK (+61.6%), HPGC Renmintongtai Pharmaceutical Corporation (+61.1%), and Chengda Pharmaceuticals Co., Ltd. (+58.3%) [2][30]. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector also outperformed, with the Hang Seng Healthcare index increasing by 6.8% and the Hong Kong Biotechnology index by 7.1% [2][31]. - In the U.S., the S&P Healthcare Select Sector rose by 3.9%, significantly outperforming the S&P 500, which only increased by 0.1% [2][32]. Valuation Metrics - As of November 14, 2025, the premium level of the pharmaceutical sector relative to all A-Shares is at a normal level, with a current relative premium rate of 77.0% [2][15]. - The report provides earnings forecasts and valuation metrics for various companies, indicating expected growth rates and price-to-earnings ratios for the coming years [6][7].

Core Viewpoint - The A-share market is experiencing a rebound with strong performance in sectors like consumer goods, food and beverage, and oil, while sectors such as communication and electronics are under pressure. The "20CM New Species" Sci-Tech Innovation Drug ETF Huatai (589120) has seen a significant inflow of funds, accumulating over 190 million yuan in nine consecutive days, with a total scale exceeding 500 million yuan [1][3]. Group 1: Market Performance - The A-share market is showing a mixed trend, with certain sectors like consumer goods and food and beverage performing strongly, while others like communication and electronics are facing challenges [1]. - The "20CM New Species" Sci-Tech Innovation Drug ETF Huatai (589120) has risen over 1% amid this market fluctuation, indicating investor interest in innovative drug sectors [1]. Group 2: Fund Inflows and Performance - The Sci-Tech Innovation Drug ETF Huatai (589120) has attracted over 190 million yuan in funds over the past nine days, reflecting strong investor confidence in the innovative drug sector [1]. - The ETF's latest scale has surpassed 500 million yuan, showcasing its growing popularity among investors [1]. Group 3: Company-Specific Developments - BeiGene reported a 41% year-on-year increase in third-quarter revenue, reaching 1.41 billion USD, primarily driven by strong sales of its drug, Zebrutinib [3]. - Several component stocks of the ETF, such as Teva Biopharma and Zai Lab, have shown positive performance, with Teva Biopharma rising over 4% [3][4]. Group 4: Policy and Market Dynamics - The National Medical Insurance Administration is conducting negotiations for the medical insurance drug catalog, with 120 companies participating, indicating a significant policy shift aimed at enhancing drug accessibility [5][6]. - The introduction of a dual catalog negotiation system allows pharmaceutical companies more strategic options, potentially leading to better market access for innovative drugs [6][7]. Group 5: Future Outlook - The innovative drug sector is expected to continue thriving, supported by favorable policies and increasing international collaboration, with projections indicating substantial market growth by 2030 [8]. - The focus on innovative drugs, particularly in the context of the upcoming medical insurance negotiations, is likely to enhance the market landscape for these products [8].